Navigation Links
Emerging lymphoma and myeloma treatments focus on improving individual patient response
Date:12/12/2011

p>

Dr. Meyer will present this study in an oral presentation on Monday, December 12, at 3:00 p.m. PST at the San Diego Convention Center in Ballroom 20A.

Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study [Abstract 269]

The first clinical trial to directly compare rituximab with the new anti-CD20 monoclonal antibody obinutuzumab for the treatment of relapsed non-Hodgkin lymphoma (NHL) has shown higher response rates for patients treated with the novel therapy.

NHL survival rates have increased dramatically in the last several decades because of such proven and effective targeted therapies as rituximab that aim directly at the key molecular features of the disease. Despite advances in NHL treatment, hematologists continue to be challenged by drug resistance and disease relapses among their patients. Obinutuzumab, also known as GA101, is a new investigational therapy and the first type II bio-engineered monoclonal antibody specifically targeting CD20 (a prominent lymphoma biomarker) to be studied for use in NHL. Early research with GA101 has shown potential anti-lymphoma activity, but no studies have compared the results against current clinical options directly.

To compare the efficacy and safety of GA101 versus rituximab in patients with relapsed NHL, an international Phase II clinical trial was undertaken measuring overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety outcomes among patients on both treatments. A total of 175 patients were randomized to receive four weekly injections of either GA101 or rituximab with response to treatment assessed between 28 and 42 days after the last dose. Those patients who responded to treatment received ongoing doses of GA101
'/>"/>

Contact: Lindsey Love
llove@hematology.org
540-538-9326
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Emerging public health crisis linked to mortgage default and foreclosure
2. Emerging pharmaceutical platform may pose risks to retinal health
3. Georgia Tech researchers receive 3 NSF Emerging Frontiers awards
4. ASCO: Emerging trends in radiation therapy for women over 70 with early stage breast cancer
5. ATS issues report on emerging issues in HIV-associated pulmonary disease
6. Emerging drug class may enhance red blood cell production in anemic patients
7. New Society for Social Neuroscience to help guide emerging field
8. Live streaming of emerging brain science and health news
9. Emerging E. coli strain causes many antimicrobial-resistant infections in US
10. Neuxpower Selected as 2010 Emerging Technology Vendor by CRN Magazine
11. Experts explore emerging evidence linking diabetes and cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a ... academic center on Wednesday, April 22. , Johnson & Wales ... available by the re-alignment of Interstate-195. JWU’s new academic building, ... Chestnut streets in Providence, is scheduled to be completed in ... land the university purchased in 2012. , “It has long ...
(Date:5/4/2015)... 04, 2015 The American Telemedicine Association ... policy reports which identify gaps in coverage and reimbursement, ... issued the State Telemedicine Gaps Reports last September, many ... laws and regulations impact healthcare delivery in their state,” ... of state actions across the nation, ATA reevaluated the ...
(Date:5/4/2015)... Switzerland (PRWEB) May 04, 2015 ... “ The Importance of Data Integrity in a ... McDowall as guest presenter. This webinar will be ... (15:00 GMT). , Data integrity is a critical ... submitted to regulatory agencies. However, in recent years ...
(Date:5/4/2015)... 04, 2015 EY today announced that ... a finalist for the EY Entrepreneur Of The Year® ... awards program recognizes entrepreneurs who demonstrate excellence and extraordinary ... personal commitment to their businesses and communities. Mr. ... of independent judges. Award winners will be announced ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2
... ,Stop wasting tax dollars on investigations, -- ... -- Three-fifths favor stripping stats and awards from ... As this year,s,Major League Baseball season-opener approaches, a ... close eye on steroid use among,professional athletes., ...
... Expects Filing of Restated Audited Financial Statements No Later Than ... April 14, 2008 - ... - Confirms 2008 Revenue Guidance -, WARSAW, Ind., March 27 ... the global,orthopedic device industry and other medical markets, today announced that,the filing of its ...
... GPRO ) announced today that the Company will ... of Molecular Diagnostics Roundtable,Conference" in New York on April ... is scheduled to be webcast live and may be ... Gen-Probe,s website,at http://www.gen-probe.com . The webcast will be ...
... 27 Radian Guaranty Inc., the,primary mortgage insurance ... ),announced today that mortgages originated under "stated income" ... for mortgage insurance. In a,message to clients this ... used to verify assets and income are appropriate,with ...
... Prevents return to work almost as often as physical ... -- Depression stops stroke victims from returning to work almost ... The study of 210 men and women, average age 55, ... of them returned to work within six months -- about ...
... UCLA used a high resolution technique to examine the genome, ... stem cell lines and found that while both lines could ... certain genes that could control such things as individual traits ... genome, which contains all the genes on 46 chromosomes, is ...
Cached Medicine News:Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 2Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 3Health News:Symmetry Medical Delays 10-K Filing to Complete Review 2Health News:Symmetry Medical Delays 10-K Filing to Complete Review 3Health News:Symmetry Medical Delays 10-K Filing to Complete Review 4Health News:Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference 2Health News:Radian Guaranty Inc. Eliminates 'Stated Income' and 'Stated Asset' Programs 2Health News:Radian Guaranty Inc. Eliminates 'Stated Income' and 'Stated Asset' Programs 3Health News:Radian Guaranty Inc. Eliminates 'Stated Income' and 'Stated Asset' Programs 4Health News:Depression After Stroke Can Be Debilitating 2Health News:UCLA researchers examine human embryonic stem cell genome 2Health News:UCLA researchers examine human embryonic stem cell genome 3
(Date:5/4/2015)... May 4, 2015 Former NASA scientist ... last week where he discussed Theradome™, the first portable ... The FOX segment shows firsthand how, via laser technology, ... loss solution that will not require surgery or medication.  ... at the base of the hair follicle, which is ...
(Date:5/4/2015)... MUNDELEIN, Ill. , May 4, 2015 ... , with live video and product demonstrations at the ... Radiology imaging equipment such as Kodak and Fuji Cr,s, ... be auctioned at the first event. Various imaging equipment ... www.RadiologyAuction.com . After years of buying ...
(Date:5/4/2015)... , May 4, 2015  Oncobiologics, Inc., a ... antibody (mAb) biosimilars, has completed the construction of ... headquarters in Cranbury, New Jersey ... facility is designed to utilize multiple technologies ... commercial scale.  Through the use of the latest ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3
... The U.S. Food and Drug Administration today is ... because the highest approved dose--80 milligram (mg)--has been associated ... particularly during the first 12 months of use. ... agency is recommending that simvastatin 80 mg be used ...
... Neurologix, Inc. (OTCBB: NRGX) announced today several new results ... its novel, investigational gene therapy NLX-P101 for the treatment ... presentation of study findings to the National Institutes of ... analysis of new data showed patients treated with NLX-P101 ...
Cached Medicine Technology:FDA Announces New Safety Recommendations for High-Dose Simvastatin 2FDA Announces New Safety Recommendations for High-Dose Simvastatin 3Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 2Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 3Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 4Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 5Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 6Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 7Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 8Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 9
Reliavac® 400cc kits with siliconized PVC drain, Y-connector tube...
Reliavac® 100cc low suction evacuator kits with flat drains and Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used in the peritoneal cavity to remove large volumes of thick exudate....
Medicine Products: